CEUS ultrasound offers superior efficacy to CT scans Contrast-enhanced ultrasound may be used to evaluate and monitor inflammatory bowel disease without exposing sufferers to CT scans or ionizing radiation, according to a report announced today at the ICUS Bubble Conference in Chicago. Stephanie Wilson, MD, Professor of Radiology, University of Calgary, Division of Diagnostic Imaging, Foothills INFIRMARY, Calgary, Canada. Wilson spoke at the 25th annual Advances in Contrast Ultrasound conference. Wilson called CEUS an ideal tool for monitoring disease activity and response to therapy over a patient’s life time, and said it is important for young patients with lifelong IBD particularly. She added that one expensive treatment options may be avoided when CEUS indicates that IBD isn’t active. Related StoriesSonaCare Medical's Sonablate 450 focused ultrasound program receives FDA approval for ablation of prostate tissueResearchers perform initial focused ultrasound remedies in the U.S.Exosome Diagnostics can be developing several assessments using the noninvasive exosome technology to measure solitary genetic mutations such as for example those within the EGFR, BRAF and KRAS genes for make use of in lung, colon, melanoma and brain cancers. The Company can be developing complicated mutational profiles of cancers tumors for monitoring disease progression and mutational position. After the extensive study referred to in the paper was finished, Exosome Diagnostics exclusively certified Massachusetts General Hospital’s provisional patent on the technology. We believe these results possess wide implications for personalized medication, stated Johan Skog, Ph.D., director of genetics at Exosome Diagnostics. Detecting mutational profiles through a non-invasive blood test could enable us to monitor what sort of tumor’s genetic makeup adjustments in response to therapy, which might necessitate adjustments in treatment strategy.